AZNAstraZenecaRunning, no new patients
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 214 (final count)
- Started
- Feb 15, 2023
- Main results expected
- Sep 30, 2026
- Fully finished
- Sep 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1
Measured over: From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 44months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05557838 · record last updated 2026-06-26 · checked 2026-11-09 15:47 UTC